WO2005099685A1 - クロモグリク酸ナトリウムを含有する液状外用剤 - Google Patents
クロモグリク酸ナトリウムを含有する液状外用剤 Download PDFInfo
- Publication number
- WO2005099685A1 WO2005099685A1 PCT/JP2004/013898 JP2004013898W WO2005099685A1 WO 2005099685 A1 WO2005099685 A1 WO 2005099685A1 JP 2004013898 W JP2004013898 W JP 2004013898W WO 2005099685 A1 WO2005099685 A1 WO 2005099685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- external preparation
- liquid external
- present
- sodium cromoglycate
- liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a liquid external preparation suitable for alleviating or treating allergic symptoms appearing in the eyes and the nasal cavity.
- Allergic symptoms such as allergic conjunctivitis and allergic rhinitis that appear in the eyes and nasal cavity not only cause rapid exhaustion of physical strength and cause fatigue, but also excessive secretion of tears and runny nose. Very unpleasant symptoms such as hosting. It is known that sodium cromoglycate effectively alleviates such allergic conditions, and has been used as an active ingredient (antiallergic agent) in eye drops, nasal drops, inhalants, etc. ing
- Patent Document 1 JP 2001-114700 A
- Patent Document 2 JP 2003-241278 A
- Patent Document 3 JP 2002-128671 A
- the present invention is attributable to the technical problems recognized in the above-mentioned prior art, that is, sodium cromoglycate in an affected part such as an eye or a nasal cavity which does not impair the antiallergic effect exhibited by sodium cromoglycate. It aims to provide a liquid external preparation that reduces both pain and itching.
- the gist of the present invention lies in a liquid external preparation containing sodium cromoglycate and mucopolysaccharide.
- an eyewash, an eye drop, and a nasal drop containing the liquid external preparation of the present invention is also provided.
- a liquid external preparation for reducing both pain and itch caused by sodium cromoglycate in an affected part such as an eye or a nasal cavity, which is an intended purpose is realized.
- the solution containing sodium cromoglycate can be applied to the eyes and nasal cavities where allergic symptoms have appeared without any resistance, and it can be expected to contribute to the improvement of the therapeutic effect. It not only improves the feeling of use, but also synergistically exerts many excellent effects in terms of medicinal properties.
- a liquid external preparation containing sodium cromoglycate and mucopolysaccharide.
- Units expressing the amounts of the components of the liquid external preparation of the present invention such as sodium cromoglycate and mucopolysaccharide, unless otherwise specified, are referred to as% by weight (%) unless otherwise specified. %).
- sodium cromoglycate contained in the liquid external preparation of the present invention refers to skin or respiratory organs. It is a compound well-known in the art as an excellent anti-allergic agent which exhibits an action of inhibiting the release of a chemical messenger such as histamine from mast cells caused by an antigen-antibody reaction upon an allergic reaction.
- the blending amount of sodium cromoglycate in the liquid external preparation of the present invention varies depending on the usage mode of the liquid external preparation of the present invention. That is, when the liquid external preparation of the present invention is used in the form of an eyewash, it is usually about 0.01 to about 1.0% by weight, preferably about 0.05 to about 0.5% by weight, from the viewpoint of obtaining a corresponding antiallergic effect. %. From the same viewpoint, when the liquid external preparation of the present invention is used in the form of an ophthalmic solution or a nasal solution, usually about 0.1 to about 5.0% by weight, preferably about 0.5 to about 2.0% by weight. Produced in a range.
- the mucopolysaccharide used in the liquid external preparation of the present invention is generally a polysaccharide obtained from a viscous secretion of an animal.
- the mucopolysaccharide has an effect of reducing irritation. It is used as a playing chemical.
- mucopolysaccharides hyaluronic acid, chondroitin, chondroitin sulfate (salt), henolin, and the like can be used in the present invention, but are not limited thereto, and only one of these is preferable. Can be used, or two or more can be used in combination.
- sodium chondroitin sulfate can be suitably used in the liquid external preparation of the present invention.
- the amount of the mucopolysaccharide in the liquid external preparation of the present invention also varies depending on the usage mode of the liquid external preparation of the present invention. That is, when the liquid external preparation of the present invention is used in the form of an eyewash, it is usually about 0.01 to about 0.1% by weight, preferably about 0.05 to about 0.1% by weight, from the viewpoint of obtaining a corresponding irritation reduction effect. %. From the same viewpoint, when the liquid external preparation of the present invention is used in the form of eye drops or nasal drops, it is usually in the range of about 0.1 to about 1.0% by weight, preferably about 0.25 to about 0.5% by weight. It is prepared by
- an antihistamine can be further added to the liquid external preparation of the present invention for the purpose of further complementing the reduction of pain and itch due to sodium cromoglycate.
- the antihistamines that can be added to the liquid external preparation of the present invention include chlorferamine maleate, diphenhydramine hydrochloride, promethazine, diphen-rubiraline hydrochloride, clemastine fumarate, iploheptin hydrochloride, diphenhydramine, and isotipendyl hydrochloride in the present invention. Available power Not limited to these, one of these can be used alone, or two or more can be used in combination.
- chlorperamine maleate can be suitably used in the liquid external preparation of the present invention.
- the compounding amount of the antihistamine in the liquid external preparation of the present invention also varies depending on the usage of the liquid external preparation of the present invention. That is, when the liquid external preparation of the present invention is used in the form of an eyewash, from the viewpoint of obtaining a corresponding antihistamine effect, it is usually about 0.001 to about 0.01% by weight, preferably about 0.003 to about 0.01% by weight. %. From the same viewpoint, when the liquid external preparation of the present invention is used in the form of eye drops or nasal drops, usually about 0.01 to about
- liquid external preparation of the present invention Unless the action and effect of the liquid external preparation of the present invention are inhibited, other components generally used in preparations applied to the eye or the nasal cavity, for example, chelating agents, solubilizing agents, The optional addition of preservatives, preservatives, buffers, thickeners, pH adjusters, and fresheners.
- sodium edetate, citrate and the like can be used in the present invention.
- the present invention is not limited to these. The above may be used in combination.
- solubilizing agent polysorbates, propylene glycol, glycerin, and the like can be used in the present invention. These are not limited to these. Any one of these may be used alone, or two or more may be used. Can also be used in combination.
- preservatives include parabens, chlorhexidine dalconate, chlorobutanol, phenol ethyl alcohol, benzyl alcohol, sodium dehydroacetate, sorbic acid, potassium sorbate, cetylpyridinium chloride, and benzethonium chloride.
- Benzolcombium chloride, chlorhexidine chloride, and the like can be used in the present invention.
- the powers that can be used in the present invention are not limited to these. More than one type can be used together.
- buffer examples include organic acids such as boric acid, citric acid, phosphoric acid, tartaric acid, acetic acid, and carbonic acid; Formic acid and salts thereof can be used in the present invention. However, the present invention is not limited to these, and any one of these can be used alone, or two or more can be used in combination.
- methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer and the like can be used in the present invention. , Or only one type may be used, or two or more types may be used in combination.
- pH adjusters include sodium hydroxide, potassium hydroxide, hydrochloric acid, citric acid (salt), boric acid (salt), phosphoric acid (salt), acetic acid (salt), tartaric acid (salt), sodium carbonate and The force by which sodium bicarbonate or the like can be used in the present invention. These forces are not limited to these, and any one of these forces can be used alone, or two or more can be used in combination.
- Examples of the freshener include menthol, camphor, borneol, gelaol, cineol, linalool, eucalyptus oil, bergamot oil, fennel oil, rose oil, and the like, which can be used in the present invention. Only one of these can be used, or two or more of them can be used in combination.
- a surfactant can be optionally added for the purpose of promoting the solubilization of these cooling agents.
- surfactants such as polyoxyethylene hydrogenated castor oil, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polysorbates, sodium lauryl sulfate and sucrose fatty acid esters can be used in the present invention.
- the present invention is not limited to these, and any one of these forces can be used alone, or two or more of them can be used in combination.
- any aqueous medium suitable as a solvent for the above-mentioned components can be used.
- Water having a low content for example, purified water, deionized water, distilled water and the like can be suitably used.
- the liquid external preparation of the present invention can be in the form of eyewash, eye drops or nasal drops.
- the liquid external preparation of the present invention When used in the form of an eye wash, apply a cup containing a few ml of the eye wash around the eyes to wash away dust and other dust attached to the eyes. At the same time, allergic symptoms of the eyes are alleviated.
- the liquid external preparation of the present invention when used in the form of eye drops or nasal drops, it can be applied to the eye or nasal cavity by an ordinary eye drop or nasal drop method.
- Example 1-2 Each of the liquid external preparations of Example 1-2 and Comparative Examples 1-2 was used as an ophthalmic solution, and the respective irritative and antipruritic items were evaluated according to the following test methods.
- each of six panelists evaluated the degree of subsidence of the itch after instillation of 121 drops of each liquid external preparation. Specifically, of the following three types of liquid preparations: "I did not feel itching at all”, “I felt very slight itching”, “Slightly itching” and “I felt quite itching” Panelists selected appropriate evaluations (expressions) as residual itch after instillation. The number of people evaluated for each criterion item was directly expressed as the evaluation result. These evaluation results are summarized in Table 2 below.
- Example 1 It became clear that the liquid topical preparations of Example 1 and 2 had very little irritation and almost no itching caused by sodium cromoglycate.
- the liquid external preparation of the present invention can sufficiently exert the antiallergic effect exhibited by sodium cromoglycate, while preventing the pain and itch appearing at the application site such as the eye and the nasal cavity due to sodium cromoglycate. Since both can be reduced, the feeling of use is very good, and it is also extremely useful as a means for alleviating allergic symptoms.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-108403 | 2004-03-31 | ||
JP2004108403A JP2005289900A (ja) | 2004-03-31 | 2004-03-31 | クロモグリク酸ナトリウムを含有する液状外用剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005099685A1 true WO2005099685A1 (ja) | 2005-10-27 |
Family
ID=35149752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013898 WO2005099685A1 (ja) | 2004-03-31 | 2004-09-24 | クロモグリク酸ナトリウムを含有する液状外用剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2005289900A (ja) |
WO (1) | WO2005099685A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0977656A (ja) * | 1995-09-14 | 1997-03-25 | Toshihiro Handa | 点眼用エアゾル組成物 |
JPH1060505A (ja) * | 1996-08-22 | 1998-03-03 | Sumitomo Metal Mining Co Ltd | 永久磁石用希土類−遷移金属系合金粉の製造方法 |
JP2003137781A (ja) * | 2001-08-20 | 2003-05-14 | Rohto Pharmaceut Co Ltd | 眼科用組成物 |
JP2003192589A (ja) * | 2001-12-27 | 2003-07-09 | Lion Corp | 外用剤組成物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3155689B2 (ja) * | 1995-08-10 | 2001-04-16 | 昭和薬品化工株式会社 | 消炎点眼剤 |
JP3402613B2 (ja) * | 1996-09-26 | 2003-05-06 | ロート製薬株式会社 | 点眼剤 |
JPH1160505A (ja) * | 1997-05-20 | 1999-03-02 | Senju Pharmaceut Co Ltd | 防腐組成物 |
JP2001097861A (ja) * | 1999-09-29 | 2001-04-10 | Lion Corp | 眼科用組成物 |
JP4757970B2 (ja) * | 1999-10-14 | 2011-08-24 | 久光製薬株式会社 | 点眼剤組成物 |
JP2001187728A (ja) * | 1999-12-28 | 2001-07-10 | Lion Corp | 眼科用組成物 |
JP5132015B2 (ja) * | 2000-10-11 | 2013-01-30 | 久光製薬株式会社 | 点眼剤組成物 |
JP2002128671A (ja) * | 2000-10-23 | 2002-05-09 | Taisho Pharmaceut Co Ltd | 点眼液 |
JP4442118B2 (ja) * | 2003-05-29 | 2010-03-31 | ゼリア新薬工業株式会社 | 安定な点眼剤 |
JP2005187407A (ja) * | 2003-12-25 | 2005-07-14 | Lion Corp | アレルギー眼疾患用眼科組成物 |
JP4789479B2 (ja) * | 2004-02-23 | 2011-10-12 | ロート製薬株式会社 | プラノプロフェン含有水性組成物 |
JP2005247795A (ja) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | 安定な点眼剤 |
JP2005314353A (ja) * | 2004-03-29 | 2005-11-10 | Rohto Pharmaceut Co Ltd | プラノプロフェン含有組成物 |
-
2004
- 2004-03-31 JP JP2004108403A patent/JP2005289900A/ja active Pending
- 2004-09-24 WO PCT/JP2004/013898 patent/WO2005099685A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0977656A (ja) * | 1995-09-14 | 1997-03-25 | Toshihiro Handa | 点眼用エアゾル組成物 |
JPH1060505A (ja) * | 1996-08-22 | 1998-03-03 | Sumitomo Metal Mining Co Ltd | 永久磁石用希土類−遷移金属系合金粉の製造方法 |
JP2003137781A (ja) * | 2001-08-20 | 2003-05-14 | Rohto Pharmaceut Co Ltd | 眼科用組成物 |
JP2003192589A (ja) * | 2001-12-27 | 2003-07-09 | Lion Corp | 外用剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2005289900A (ja) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10183076B2 (en) | Topical compositions for treatment of irritation of mucous membranes | |
KR101690817B1 (ko) | 안과용 조성물 | |
KR101821518B1 (ko) | 고농도 올로파타딘 안과용 조성물 | |
JP2001187728A (ja) | 眼科用組成物 | |
JP2004514731A (ja) | 眼薬送達のための可逆的ゲル化システム | |
JP3402613B2 (ja) | 点眼剤 | |
JP3142842B1 (ja) | 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法 | |
JP2002097129A (ja) | 点眼剤 | |
JP4725699B2 (ja) | 眼科用組成物及び眼科用組成物配合用防腐剤 | |
WO2000016771A1 (fr) | Preparations liquides a usage externe contenant du cromoglycate de sodium et traitement ou prevention des symptomes allergiques oculaires | |
JP4905616B2 (ja) | ソフトコンタクトレンズ用点眼剤 | |
JP2002212107A (ja) | 局所適用組成物 | |
JP2003002837A (ja) | 水性外用剤組成物及び液体組成物の白濁防止方法 | |
JP2001322936A (ja) | 眼科用組成物 | |
JP2002114686A (ja) | 点眼剤組成物 | |
JP5041761B2 (ja) | 眼粘膜適用製剤 | |
JP4801300B2 (ja) | 外用液状組成物 | |
WO2005099685A1 (ja) | クロモグリク酸ナトリウムを含有する液状外用剤 | |
JP2005008596A (ja) | 眼科用組成物 | |
US20090270335A1 (en) | Collyrium for dry eye | |
JP5713034B2 (ja) | 眼科用組成物、及び眼科製剤用防腐組成物 | |
JPH01224321A (ja) | 点眼剤 | |
WO2005100362A1 (ja) | プラノプロフェンを含有する液状外用剤 | |
JP2009084235A (ja) | 眼科用抗充血剤及び抗充血用眼科組成物 | |
JP2001354592A (ja) | 点眼剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |